WeLeader Biomedical Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2022	FY 2021
Period Ending	Sep '23 Sep 30, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	954.87	1,036	841.14
Revenue Growth (YoY)	13.52%	23.13%	-
Cost of Revenue	663.26	743.97	622.22
Gross Profit	291.61	291.75	218.92
Selling, General & Admin	98.44	97.64	86.26
Operating Expenses	97.89	97.11	86.65
Operating Income	193.72	194.64	132.28
Interest Expense	-4.37	-4.21	-6.16
Interest & Investment Income	0.41	0.24	0.08
Other Non Operating Income (Expenses)	2.03	1.88	4.85
EBT Excluding Unusual Items	191.79	192.54	131.04
Gain (Loss) on Sale of Investments	-0.15	-0.68	0.01
Gain (Loss) on Sale of Assets	0.03	0.69	0.41
Pretax Income	191.67	192.55	131.46
Income Tax Expense	41.01	38.75	25.69
Net Income	150.66	153.8	105.77
Net Income to Common	150.66	153.8	105.77
Net Income Growth	42.44%	45.40%	-
Shares Outstanding (Basic)	37	30	28
Shares Outstanding (Diluted)	37	30	28
Shares Change (YoY)	32.55%	8.28%	-
EPS (Basic)	4.08	5.13	3.79
EPS (Diluted)	4.04	5.05	3.76
EPS Growth	7.50%	34.31%	-
Free Cash Flow	-46.95	-379.09	216.43
Free Cash Flow Per Share	-1.26	-12.46	7.70
Dividend Per Share	0.860	0.860	0.450
Dividend Growth	91.11%	91.11%	-
Gross Margin	30.54%	28.17%	26.03%
Operating Margin	20.29%	18.79%	15.73%
Profit Margin	15.78%	14.85%	12.57%
Free Cash Flow Margin	-4.92%	-36.60%	25.73%
EBITDA	224.65	226.65	165.64
EBITDA Margin	23.53%	21.88%	19.69%
D&A For EBITDA	30.93	32.01	33.36
EBIT	193.72	194.64	132.28
EBIT Margin	20.29%	18.79%	15.73%
Effective Tax Rate	21.40%	20.12%	19.54%

Source: S&P Capital IQ. Standard template. Financial Sources.